Galactose binds to focal segmental glomerulosclerosis permeability factor and inhibits its activity

Translational Research

Volumn 151, Issue 6, 2008, Pages 288-292

  Savin, Virginia J ^a   McCarthy, Ellen T ^a   Sharma, Ram ^a   Charba, Deane ^a   Sharma, Mukut ^a  

^a MEDICAL COLLEGE OF WISCONSIN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

FOCAL SEGMENTAL GLOMERULOSCLEROSIS PERMEABILITY FACTOR; GALACTOSE; MEMBRANE PROTEIN;

ADULT; ARTICLE; BINDING AFFINITY; CASE REPORT; COLUMN CHROMATOGRAPHY; DRUG EFFECT; DRUG EFFICACY; FOCAL GLOMERULOSCLEROSIS; GLYCOCALYX; HUMAN; MALE; MEMBRANE FILTER; NEPHROTIC SYNDROME; PRIORITY JOURNAL; PROTEIN CARBOHYDRATE INTERACTION; PROTEIN DEGRADATION; PROTEIN FUNCTION; SERUM; TREATMENT OUTCOME;

EID: 50949086886     PISSN: 19315244     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.trsl.2008.04.001     Document Type: Article

References (16)

1. Meyrier A. Mechanisms of disease: focal segmental glomerulosclerosis. Nat Clin Pract Nephrol 1 (2005) 44-54
2. Fine R.N. Recurrence of nephrotic syndrome/focal segmental glomerulosclerosis following renal transplantation in children. Pediatr Nephrol 22 (2007) 496-502
3. Hoyer J.R., Vernier R.L., Najarian J.S., Raij L., Simmons R.L., and Michael A.F. Recurrence of idiopathic nephrotic syndrome after renal transplantation. J Am Soc Nephrol 12 (2001) 1994-2002
4. Artero M.L., Sharma R., Savin V.J., and Vincenti F. Plasmapheresis reduces proteinuria, serum capacity to injure glomeruli in patients with recurrent focal glomerulosclerosis. Am J Kidney Dis 23 (1994) 574-581
5. Haas M., Godfrin Y., Oberbauer R., et al. Plasma immunadsorption treatment in patients with primary focal and segmental glomerulosclerosis. Nephrol Dial Transplant 13 (1998) 2013-2016
6. Gohh R.Y., Yango A.F., Morrissey P.E., et al. Preemptive plasmapheresis and recurrence of FSGS in high-risk renal transplant recipients. Am J Transplant 5 (2005) 2907-2912
7. Savin V.J., Sharma R., Sharma M., et al. Circulating factor increasing glomerular permeability in recurrent focal segmental glomerulosclerosis. N Engl J Med 334 (1996) 878-883
8. Sharma M., Sharma R., Reddy S.R., McCarthy E.T., and Savin V.J. Proteinuria after injection of human focal sclerosis factor. Transplantation 73 (2002) 366-372
9. Sharma M., Sharma R., McCarthy E.T., and Savin V.J. The focal segmental glomerulosclerosis permeability factor: biochemical characteristics and biological effects. Exp Biol Med 229 (2004) 85-98
10. Savin V.J., Sharma R., Lovell H.B., and Welling D.J. Measurement of albumin reflection coefficient with isolated rat glomeruli. J Am Soc Nephrol 3 (1992) 1260-1269
11. alb) in minimal change nephrotic syndrome is permanently lost after successful treatment of Hodgkin's disease. Am J Kidney Dis 50 (2007) 826-829
12. Cattran D., Neogi T., McCarthy E.T., Savin V.J., and Sharma R. Serial estimates of serum permeability activity and clinical correlates in patients with native kidney focal segmental glomerulosclerosis. J Am Soc Nephrol 14 (2003) 448-453
13. Feld S.M., Figueroa P., Savin V., et al. Plasmapheresis in the treatment of steroid-resistant focal segmental glomerulosclerosis in native kidneys. Am J Kidney Dis 32 (1998) 230-237
14. Schmieder S., Nagai M., Orlando R.A., Takeda T., and Farquhar M.G. Podocalyxin activates RhoA and induces actin reorganization through NHERF1 and Ezrin in MDCK cells. J Am Soc Nephrol 15 (2004) 2289-2298
15. Weigel P.H., and Yik J.H. Glycans as endocytosis signals: the cases of the asialoglycoprotein and hyaluronan/chondroitin sulfate receptors. Biochim Biophys Acta 1572 (2002) 341-363
16. Frustaci A., Chimenti C., Ricci R., et al. Improvement in cardiac function in the cardiac variant of Fabry's disease with galactose-infusion therapy. N Engl J Med 345 (2001) 25-32